Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene.
(2013) Journal of neurology — Vol. 260, n° 4, p. 1116-1121 (2013)
Files
2013_Saccà_J_Neurol.pdf
Restricted Access - Adobe PDF
- 348.91 KB
Details
- Authors
- Abstract
- Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 % of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 % of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. L-Buthionine-sulphoximine treatment of the proband's lymphoblasts showed a severe phenotype as compared to classic FRDA.
- Affiliations
University Federico II Department of Neurological Sciences
Citations
Saccà, F., Marsili, A., Puorro, G., Antenora, A., Pane, C., Tessa, A., Scoppettuolo, P., Nesti, C., Brescia Morra, V., De Michele, G., Santorelli, F. M., & Filla, A. (2013). Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. Journal of neurology, 260(4), 1116-1121. https://doi.org/10.1007/s00415-012-6770-5 (Original work published 2013)